

# Press Release

## Cellzome Extends Drug Discovery Collaboration

**Boston, 10<sup>th</sup> July 2008** - Cellzome Inc. announced today that its collaboration in Alzheimer's Disease with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJP) and its affiliate, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), is being extended for a further two years until March 2010. In addition, the collaboration is being expanded to include an additional research programme in which Cellzome will map the Tau pathway, also associated with Alzheimer's disease.

Cellzome and J&JPRD have been jointly progressing two research programmes in Alzheimer's Disease since early 2005. In the first programme, J&JPRD and Cellzome have collaborated to identify and progress novel Gamma Secretase Modulators. In the second, they are jointly selecting and progressing novel targets from the Amyloid Precursor Protein (APP) pathway, previously mapped by Cellzome.

As part of the agreement, OMJP has exclusive rights to the intellectual property on compounds chosen for clinical development and commercialisation. In exchange, Cellzome receives a technology access fee and research support as well as milestones and royalties on sales. Further financial details are not disclosed.

Tim Edwards, Cellzome's CEO, said, "I am pleased to be extending our collaboration with J&JPRD for the second time. I look forward to working with J&JPRD over the next two years to advance these novel molecules, for the potential benefit of patients."

### About Cellzome Inc.

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by *Kinobeads*<sup>TM</sup>, a proprietary technology for screening and profiling of kinases in relevant cells and tissues.

Cellzome is applying its distinctive *Kinobeads*<sup>TM</sup> technology to the discovery and development of novel, selective kinase inhibitors targeting key inflammatory mediators in immune receptor signaling and chemotaxis, such as PI3Kgamma and delta, Zap-70 and mTOR.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: [www.cellzome.com](http://www.cellzome.com).

### About Alzheimer's Disease

Alzheimer's Disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills. It is the most common cause of dementia in older people. About 20 million people are affected worldwide and at the current rate the number is expected to double by 2025. In the United States alone, more than 4.5 million people are currently afflicted with the disorder, resulting in healthcare costs of close to \$100 billion annually. The AD therapeutic market is currently valued at about \$4.7 billion in the major markets (US, UK, Germany, France, Italy, Spain and Japan) and is expected to increase to \$7.8 billion by the year 2010.

### For further information please contact:

#### Cellzome AG

Tim Edwards  
Chief Executive Officer  
Tel: +49 (0) 6221-137 57-100  
[press@cellzome.com](mailto:press@cellzome.com)

#### Media Contact

**Hogarth Partnership**  
Sarah MacLeod  
Tel: +44 (0) 207 357 9477  
[SMacleod@hogarthpr.co.uk](mailto:SMacleod@hogarthpr.co.uk)